NewsBenzingaEledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026 Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026 Benzinga 2026.09.22 11:10 (GMT+0) Open on Benzinga Other news Freshworks Stock Has Strong Momentum at New 52-Week Highs, But There’s 1 Reason for Caution Why Is Snowflake Stock Surging Monday? 18 Globo Titles Heading To Netflix In Unprecedented Licensing Agreement ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment RBC Capital Maintains Outperform on Regions Financial, Lowers Price Target to $32 Wells Fargo Maintains Equal-Weight on Greif, Lowers Price Target to $88
